These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19755410)

  • 1. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
    Malmgren S; Ahrén B
    Diabetologia; 2015 May; 58(5):1091-9. PubMed ID: 25660260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
    Miura K; Kitahara Y; Yamagishi S
    Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
    Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
    Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
    Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
    PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
    Omar BA; Liehua L; Yamada Y; Seino Y; Marchetti P; Ahrén B
    Diabetologia; 2014 Sep; 57(9):1876-83. PubMed ID: 24939431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.